Tirzepatide 45MG — 5 Vial Bulk Pack

Tirzepatide 90MG

Tirzepatide (LY3298176) is a synthetic dual incretin receptor agonist peptide that activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent
insulinotropic polypeptide) receptors. This product is typically supplied in a 90 mg lyophilized vial (or as part of bulk/multi-vial formats) for reconstitution
and is sold exclusively for laboratory and preclinical research purposes in accredited scientific institutions, qualified academic laboratories, or approved
research settings. It is not approved for human use, diagnostic purposes, therapeutic applications, or consumption by humans or animals.

Research Context

Tirzepatide is a first-in-class dual GLP-1/GIP receptor agonist developed by Eli Lilly and Company. It enhances incretin effects to promote insulin secretion in
a glucose-dependent manner, suppress glucagon, slow gastric emptying, reduce appetite, and support energy homeostasis. While now an approved therapeutic agent for
certain indications, research-grade forms (high-content vials like 90 mg) remain valuable for basic mechanistic studies, receptor binding assays,
pharmacokinetics/pharmacodynamics modeling, formulation development, comparative incretin research, and non-clinical models of metabolic disorders.

As of February 2026, tirzepatide is FDA-approved under the brand names:

• Mounjaro (approved May 2022) — for improving glycemic control in adults with type 2 diabetes.
• Zepbound (approved November 2023) — for chronic weight management in adults with obesity or overweight with weight-related conditions; expanded in
  December 2024 to include moderate-to-severe obstructive sleep apnea in combination with diet and exercise.

Recent updates include FDA label expansion (February 23, 2026) for a multi-dose KwikPen delivering a full month’s treatment (4 doses in one single-patient-use
device). It remains the most prescribed weight management medication in the U.S. (2025 data), with ongoing real-world evidence, post-marketing studies, and
combination trials (e.g., with ixekizumab for psoriasis and obesity, showing superior skin clearance and weight loss in February 2026 Phase 3b results).

Current Research Overview (as of February 2026)

• Pivotal Phase 3 SURMOUNT trials demonstrated substantial weight loss: e.g., in SURMOUNT-1 (adults without diabetes), up to ~20.9% average body weight reduction
  (≈48 lb) at 72 weeks with 15 mg dose. SURMOUNT-5 head-to-head vs. semaglutide showed ~20.2% loss (50 lb) vs. ~13.7% (33 lb). Long-term data confirm sustained
  benefits and diabetes prevention.
• Additional indications supported by trials: reductions in cardiometabolic risks, hepatic fat, and improvements in sleep apnea.
• Potential benefits under investigation in research settings include:
• Superior incretin-mediated effects vs. single GLP-1 agonists
• Central nervous system modulation of appetite via hypothalamic pathways
• Favorable impacts on lipid profiles, insulin sensitivity, and inflammation
• Once-weekly subcutaneous administration

Key Research Focus Areas (Updated Status)

Important Notes

• Approved therapeutic doses titrate up to 15 mg weekly (not 90 mg as a single dose). The 90 mg vial is common for research reconstitution, in vitro assays,
  animal model dosing, bulk peptide studies, or high-throughput screening—not indicative of human clinical dosing.
• Research must strictly comply with institutional, local, and international regulations for handling synthetic peptides, including proper storage (lyophilized:
  frozen/refrigerated; reconstituted: refrigerated with appropriate stabilizers), reconstitution protocols (e.g., bacteriostatic water), animal welfare standards
  (if applicable), and waste disposal.
• Potential off-target effects, receptor specificity, and long-term impacts require rigorous controlled evaluation.
• For research use only. Not for human or veterinary use. Not for diagnostic or therapeutic purposes. Suppliers of research-grade tirzepatide assume no liability
  for misuse outside legitimate laboratory environments. Obtain only from reputable vendors with third-party purity testing (e.g., ≥99% by HPLC) to ensure quality
  and compliance. Beware of unregulated sources.

This update reflects the latest publicly available data from Eli Lilly announcements, FDA approvals, clinical trial results, and peer-reviewed sources through
late February 2026. For the most current information, consult primary sources such as ClinicalTrials.gov, Lilly investor releases, or FDA databases.